literature

HIV mutation literature information.

HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.

PMID: 31117863 2019 Journal of the International Association of Providers of AIDS Care

Table: A62V

Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.

PMID: 29846534 2019 Clinical infectious diseases

Method: Several additional DRMs not on the SDRM list were analyzed including (1) the primarily tenofovir disoproxil fumarate (TDF)-selected DRMs A62V, K65N, and K70G/N/Q/S/T and (2) the primarily rilpivirine (RPV)-selected DRMs E138A/G/K/Q, of which E138A is polymorphic, occurring in 1%-4% of viruses from ART-naive individuals.

Result: A62V, a non-SDRM TDF-associated accessory DRM, occurred in 10 individuals.

Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.

PMID: 31751428 2019 PloS one

Table: A62V

Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.

PMID: 29977795 2018 African journal of laboratory medicine

Result: Other minority mutations including M41L, A62V, D67N, T69D, V75M, T215F and K219E were found in one sample each.

Table: A62V

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.

PMID: 29661246 2018 AIDS research and therapy

Result: Data regarding accessory mutations to Q151M were available in 155 (86%) patients: A62V was present in 49 (32%), V75I in 62 (40%), F77L in 47 (30%) and F116Y in 99 (64%), and 75% of patients showed at least one accessory mutation.

Table: A62V

Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.

PMID: 29084434 2018 AIDS research and human retroviruses

Introduction: However, in the 31 patients with no K65R present at S2, 6 had intermediate or high-level resistance to AZT: 4 were caused by TAM-2 DRMs, 1 by T215Y, and 1 by Q151M-complex mutations Q151M, A62V, V75I, F77L, F116Y.

HIV-1C proviral DNA for detection of drug resistance mutations.

PMID: 30286160 2018 PloS one

Abstract: While mutations G190A and E138A

Result: G190A, E138A/G) were found concurrently both in viral RNA and proviral DNA, in two patients resistance mutations (M46I and G190E) were detected only in viral RNA, and in five patients archived transmitted drug resistance mutations (M230I, G73S, M184I, M46I, and A62V) in proviral DNA were identified.

Result: NRTIs related mutations M184I and A62V were only found in proviral DNA (Table 2).

The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations.

PMID: 30029500 2018 Viruses

Result: In contrast, the two MDR complexes with A62V, as well as the A62V mutant, had a reduced replication capacity compared to that of wt virus (Figure 3).

Result: In the absence of AZT, the A62V mutant alone had significantly reduced viral replication fitness, while the T69SSS insertion complex with A62V had a non-statistically significant decrease in fitness (Figure 5A).

Result: In the presence of AZT, all MDR mutant complexes, except for the T69SSS insertion complex without A62V, had a statistically significant increase in virus fitness (Figure 5B).

Result: In this assay, all four MDR mutants (i.e., Q151M complex with or without A62V, and the

PMID: 30409215 2018 AIDS research and therapy

Result: Most of the minority mutations in viruses from both groups of naive patients were observed in the RT, e.g., M41L, E44D, A62V, K65R, D67N, D67G, V75I, L100I, K103N, K103R, V188I, M184I, L210W, K219Q, Y318F, etc., although a number of minority mutations associated with resistance to PI (L10F, V11I, M46I/

Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.

PMID: 29126456 2017 BMC research notes

Abstract: Overall, 32% (37/116) patients presented >= one major drug resistant mutation(s), with 29% (34/116) to nucleos(t)ide reverse transcriptase inhibitors (67% [29/43] M184V/I, 30% [13/43] T215Y/F, 19% [8/43] V75A/F/I/L/M, 9% [4/43] K70P/R/W, 9% [4/43] K219E/N/Q and 5% [2/43] A62V); 86% (37/43) to non-nulceos(t)ide reverse transcriptase inhibitors (30% [13/43] K103N/S/E, 26% [11/43] Y181C/V/F/L, 2% [1/43] L100I, 2% [1/43] F227L, 2% [1/43] P225H); and 2% (1/43

Browser Board

Co-occurred Entities

Filtrator